Targeted Cancer Therapy

+ -Text Size


To learn more

More information from your American Cancer Society

We have a lot more information that you might find helpful. Explore or call our National Cancer Information Center toll-free number, 1-800-227-2345. We’re here to help you any time, day or night.

National organizations and websites*

Along with the American Cancer Society, other sources of information and support include:

National Cancer Institute
Toll-free number: 1-800-4-CANCER 1-800-422-6237

    For up-to-date cancer information, including information for caregivers and family members, and to find a clinical trial that may be right for you

Job Accommodation Network
Toll-free number: 1-800-526-7234
TTY: 1-877-781-9403

    A free consulting service of the US Department of Labor that gives information to help you keep your job (and insurance) during cancer treatment. Offers information on your rights under the Americans with Disabilities Act, and how to talk with your employer

*Inclusion on this list does not imply endorsement by the American Cancer Society.

No matter who you are, we can help. Contact us anytime, day or night, for cancer-related information and support. Call us at 1-800-227-2345 or visit


Agha R, Kinahan K, Bennett CL, Lacouture ME. Dermatologic challenges in cancer patients and survivors. Oncology. 2007;21:1462-1472.

Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol. 2008;26:3460-3462.

Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer. J Natl Compr Canc Netw. 2009;7 Suppl 1:S5-S21.

Community Oncology Conference Highlights. Managing toxicities of EGFR inhibitors. 2008;5:202-203.

Esper P, Gale D, Muehlbauer P. What kind of rash is it? Deciphering the dermatologic toxicities of biologic and targeted therapies. Clin J Oncol Nurs. 2007;11:659-666.

Kyriakou F, Kountourakis P, Papamichael D. Targeted agents: Review of toxicity in the elderly metastatic colorectal cancer patients. Targ Oncol. 2011;6:245-251.

Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351-1357.

Lacouture ME, West DP, Tigue CC, Knox K, Bennett CL. Cutaneous toxicities of targeted cancer therapies. Community Oncol. 2008;5:413-414.

Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol. 2009;4:107-119.

Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist. 2007;12:610-621.

Moore SH, O’Connell MJ, Wilkes GM. Optimizing Outcomes for Metastatic Colorectal Cancer Patients: An APN Roundtable Discussion. Institute for Medical Education & Research. March 2008.

National Cancer Institute. Targeted Cancer Therapies. 2014. Accessed at on November 12, 2014.

Ocvirk J, Heeger S, McCloud P, Hofheinz RD. A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis. Radiol Oncol. 2013;47:166-175.

Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745. Epub 2013 Jan 14.

Last Medical Review: 12/08/2014
Last Revised: 12/11/2014